Skip to main content
. 2020 Mar 16;180(5):795–797. doi: 10.1001/jamainternmed.2020.0051

Figure 2. Representativeness of the Systolic Blood Pressure Intervention Trial and Action to Control Cardiovascular Risk in Diabetes Trial in US Adults Recommended Additional Antihypertensive Pharmacologic Treatment by the ACC/AHA Guideline.

Figure 2.

The 2017 American College of Cardiology/American Heart Association (ACC/AHA) guideline defines hypertension based on blood pressure (BP) level above 130/80 mm Hg. The ACC/AHA guideline recommends pharmacologic therapy to all patients whose BP level is greater than 140/90 mm Hg and to patients whose BP level is between 130-139/80-89 mm Hg if they have a history of diabetes, are older than 65 years, or have a 10-year cardiovascular disease risk of more than 10% by pooled cohort risk equations. National Health and Nutrition Examination Survey analysis includes individuals with BP level higher than 130/80 mm Hg and those reporting use of BP medications regardless of measured BP. Individuals classified as recommended additional antihypertensive pharmacologic treatment include those not previously taking any antihypertensives and those currently taking antihypertensives but above ACC/AHA guideline goal.